The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization. 

Related News Articles

Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
AHA is looking forward to spring and March Madness in its latest social media toolkit for hospitals’ and health systems’ use to promote vaccination against the…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
The Centers for Disease Control and Prevention has released a five-part webinar series on its Hospital Sepsis Program Core Elements, which offer guidance to…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…
Headline
Flu-associated medical visits and hospitalizations per 100,000 population in 2022-23 were higher among children under age 5 than for older children, but were…